Benefit-Risk Assessment of LeflunomideAn Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing

被引：0
|
作者：
Nicola Alcorn
Sarah Saunders
Rajan Madhok
机构：
[1] Glasgow Royal Infirmary,The Centre for Rheumatic Diseases
来源：
Drug Safety | 2009年 / 32卷
关键词：
Rheumatoid Arthritis; Infliximab; Interstitial Lung Disease; Rheumatol; Sulfasalazine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Evidence is accumulating for the early sustained usage of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis. Leflunomide was licensed for the treatment of rheumatoid arthritis in 1998. Postmarketing surveillance, case reports and observational studies have highlighted less common or unexpected adverse events. Therefore, it is appropriate that we review the benefit-risk profile of leflunomide after 10 years of widespread usage. A wide-based search of relevant literature was performed to formulate this assessment.
引用
收藏
页码：1123 / 1134
页数：11
相关论文
共 23 条
  • [1] Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
    Ted R. Mikuls
    Larry W. Moreland
    Drug Safety, 2003, 26 : 23 - 32
  • [2] Benefit/risk of leflunomide in rheumatoid arthritis
    Kremer, JM
    Cannon, GW
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (05) : S95 - S100
  • [3] Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?
    Avouac, Jerome
    JOINT BONE SPINE, 2022, 89 (06)
  • [4] Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis
    Xiang, Gao
    Gao, Min
    Qin, Huirong
    Shen, Xiaolan
    Huang, Huilian
    Hou, Xiaoqiang
    Feng, Zhitao
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2023, 23 (01)
  • [5] Benefit-risk assessment of traditional Chinese medicine preparations of sinomenine using multicriteria decision analysis (MCDA) for patients with rheumatoid arthritis
    Gao Xiang
    Min Gao
    Huirong Qin
    Xiaolan Shen
    Huilian Huang
    Xiaoqiang Hou
    Zhitao Feng
    BMC Complementary Medicine and Therapies, 23
  • [6] Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Conaghan, Philip
    Cohen, Stanley
    Burmester, Gerd
    Mysler, Eduardo
    Nash, Peter
    Tanaka, Yoshiya
    Rigby, William
    Patel, Jayeshkumar
    Shaw, Tim
    Betts, Keith A.
    Patel, Pankaj
    Liu, Jianzhong
    Sun, Rochelle
    Fleischmann, Roy
    RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 191 - 206
  • [7] Work disability in rheumatoid arthritis 10 years after the diagnosis
    Sokka, T
    Kautiainen, H
    Möttönen, T
    Hannonen, P
    JOURNAL OF RHEUMATOLOGY, 1999, 26 (08) : 1681 - 1685
  • [8] Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
    M. Elaine Husni
    Keith A. Betts
    Jenny Griffith
    Yan Song
    Arijit Ganguli
    Rheumatology International, 2017, 37 : 1423 - 1434
  • [9] Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective
    Husni, M. Elaine
    Betts, Keith A.
    Griffith, Jenny
    Song, Yan
    Ganguli, Arijit
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (09) : 1423 - 1434
  • [10] Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis
    Tanaka, N
    Sakahashi, H
    Sato, E
    Hirose, K
    Ishima, T
    Ishii, S
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2003, 9 (02) : 115 - 118
123